- Home
- DIAX vs RGNX Comparison
DIAX vs RGNX Comparison
Compare DIAX & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DIAX
- RGNX
- Stock Information
- Founded
- DIAX 2005
- RGNX 2008
- Country
- DIAX United States
- RGNX United States
- Employees
- DIAX N/A
- RGNX N/A
- Industry
- DIAX Finance Companies
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DIAX Finance
- RGNX Health Care
- Exchange
- DIAX Nasdaq
- RGNX Nasdaq
- Market Cap
- DIAX 477.5M
- RGNX 387.0M
- IPO Year
- DIAX N/A
- RGNX 2015
- Fundamental
- Price
- DIAX $14.01
- RGNX $7.52
- Analyst Decision
- DIAX
- RGNX Strong Buy
- Analyst Count
- DIAX 0
- RGNX 8
- Target Price
- DIAX N/A
- RGNX $31.75
- AVG Volume (30 Days)
- DIAX 96.6K
- RGNX 1.1M
- Earning Date
- DIAX 01-01-0001
- RGNX 05-12-2025
- Dividend Yield
- DIAX 7.93%
- RGNX N/A
- EPS Growth
- DIAX N/A
- RGNX N/A
- EPS
- DIAX N/A
- RGNX N/A
- Revenue
- DIAX N/A
- RGNX $83,328,000.00
- Revenue This Year
- DIAX N/A
- RGNX $285.14
- Revenue Next Year
- DIAX N/A
- RGNX N/A
- P/E Ratio
- DIAX N/A
- RGNX N/A
- Revenue Growth
- DIAX N/A
- RGNX N/A
- 52 Week Low
- DIAX $12.80
- RGNX $5.04
- 52 Week High
- DIAX $15.12
- RGNX $17.52
- Technical
- Relative Strength Index (RSI)
- DIAX 52.21
- RGNX 46.69
- Support Level
- DIAX $13.88
- RGNX $6.89
- Resistance Level
- DIAX $14.17
- RGNX $10.59
- Average True Range (ATR)
- DIAX 0.16
- RGNX 0.79
- MACD
- DIAX 0.07
- RGNX -0.19
- Stochastic Oscillator
- DIAX 83.33
- RGNX 20.67
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.